Amneal Pharmaceuticals

It’s hard to believe that 10 years have passed since Amneal Pharmaceuticals first launched its label and began directly supplying global patients with quality generic pharmaceuticals. Yet it’s true—and what a decade it’s been.

Today, as the fifth largest generic manufacturer by extended units and the fastest-growing generics company in the United States (according to April IMS data), Amneal maintains powerful R & D, efficient production, strategic sourcing, and a fine-tuned sales operation/logistics engine that puts operational muscle behind every purposeful step.

Amneal’s aggressive growth curve shows no signs of slowing. In fact, this year alone, the company is well on track to meeting its goal to launch 60 new products in the United States. This lineup includes some impressive first-to-file and first-to-market products, as well as new dosage forms and a significantly expanded Women’s Health product line.

A DECADE OF DEDICATION

What’s propelling this pharma powerhouse’s success? These 3 things, among others:

Quality, Above All

Amneal is committed to providing superb-quality products across all dosage forms. Over the years, the company has been investing in science, equipment, and intense processes to ensure exceptional quality for every commercial product launched. In addition, Amneal has released products across many complex dosage forms and technologies, such as injectables, topicals, transdermals, inhalations, and complex molecules. That same commitment to quality spans the entire organization. Since its founding, Amneal has had 57 inspections without any significant 483s across its 10 FDA-approved facilities. This uncompromising pursuit of excellence—throughout every aspect of the manufacturing process—translates into higher-quality pharmaceuticals that can be confidently given to patients, families, and loved ones.

Relentless Focus on Customer Satisfaction

Customer collaboration is at the center of everything Amneal does, especially logistics. So, when customers have a challenge that slows their supply chain, Amneal dives in and doesn’t stop until a solution is found. Amneal has countless examples of tweaking a process or investing in new systems—all to ease a customer pain point, no matter how small. Every day, Amneal asks, “How can we improve each aspect of our operation to create more value for our customers?” In a world of “good enough,” Amneal stands apart with its commitment to excellence.

Investing to Stay Ahead

Always focused on growth strategy, Amneal makes significant investments in R & D and infrastructure. From the very start—even before launching its own label—Amneal has reinvested heavily, with a staggering percentage of its revenue, in growing and broadening its product portfolio across all dosage forms and therapeutic categories. Simultaneously, the company continues to expand and enhance infrastructure in order to comfortably serve future growth, thus ensuring the capacity to meet anticipated product approvals.

“We are very excited to celebrate our 10th anniversary— a milestone that affirms our mission and desire to provide greater access to safe and affordable medicines for people around the world,” said Jim Luce, Amneal executive vice president. “We believe by focusing on our customers and patients, and standing by the values of quality and integrity, this path will allow us to continue sustaining our growth for years to come.”